WALTHAM, Mass.– Revvity, Inc. (NYSE: RVTY) announced the debut of Living Image Synergy AI, a new multimodal analysis software designed to transform in vivo imaging research. The platform integrates artificial intelligence to streamline workflows and improve reproducibility across optical, microCT, ultrasound, and other imaging modalities.
The company said the new solution reduces data inconsistencies, accelerates analysis, and enhances throughput, giving researchers the ability to generate insights more quickly and with greater confidence.
“Our Living Image Synergy AI software marks a significant leap forward in preclinical imaging analysis,” said Kevin Quick, vice president of platforms at Revvity. “Tracking, monitoring, and visualizing biological processes and disease progression is central to understanding complex biology and evaluating potential therapeutics early in development. By unifying disparate analysis tools and integrating AI into existing workflows, Revvity’s new solution is directed towards enabling earlier insights and more consistent analysis across modalities, and greater reproducibility across studies—ultimately helping researchers move faster and with more confidence.”
The software centralizes data analysis with the goal of eliminating the need for multiple separate tools, enabling seamless correlation of datasets across imaging systems. According to Revvity, this unified approach allows scientists to uncover biological insights that might otherwise be missed when using siloed platforms.
Living Image Synergy AI also incorporates co-registration tools and automated processes to minimize manual steps and analysis time. AI-driven segmentation and region-of-interest quantification—tasks that are typically labor-intensive and variable—are automated, supporting high-throughput research and enabling more accurate monitoring of disease progression and therapeutic response.
